The global market for Anti-Biofilm Wound Dressing is likely to achieve a value of US$ 2,198 Million by 2030 from US$ 990 Million in 2021 and it is expected to grow at a CAGR of 9.5% from 2022 to 2030.

Biofilm formation in wounds is now recognized as a risk factor for infection and a reason of delayed healing. To disrupt and kill biofilm bacteria, a next-generation antibiofilm carboxymethylcellulose silver-containing wound dressing (NGAD) has been created. The goal of this in vitro study was to compare its efficacy to that of other wound dressings and to look into its mechanism of action. Before being exposed to test dressings, a series of biofilm models of rising complexity were utilized to develop biofilms of wound-relevant bacteria. To evaluate dressing antibiofilm effectiveness, researchers used confocal microscopy, imaging and staining of biofilm constituents, total viable counts, and elemental analysis.

Market Dynamics

The management of acute and chronic infected wounds with a lingering biofilm remains a serious medical issue. Antimicrobial dressing interactions with bacterial load, biofilm matrix, and the overall protein-rich wound milieu are still poorly understood. Using an in vitro biofilm model (lhBIOM) that mimicked the particular biofilm environment in human wounds, this study aimed to extend the investigation into the efficiency of a variety of antimicrobial dressings.

Treatment for chronic wounds is getting more complex and expensive, which is aggravated when wounds gets infected. Bacterial biofilms are the most common cause of chronic wound infectivity, and they are disgracefully resistant to antibiotics. Honey is being reconsidered as a therapy option as a result of its wide-ranging antibacterial action and low proclivity for bacterial resistance, as well as the need for novel techniques to attack polymicrobial biofilms in chronic wounds and the developing antimicrobial resistance dilemma.

The presence of biofilm in non-healing injuries is becoming more widely familiar, and the biofilm impact and subsequent tolerance to antimicrobial drugs are most likely to blame for infection persistence and recurrence. In light of this, there is a clear clinical need to improve antimicrobial efficacy (both antibiotics and antiseptics) by adding antibiofilm chemicals that can break down biofilm in wounds and expose related microorganisms to antimicrobial attack. Chronic wound treatment and management is becoming a more challenging and expensive problem, which is aggravated when the wounds get infected. Bacterial biofilms, in which cells are embedded in a matrix of exopolysaccharides and other elements such as proteins, DNA, and membrane vesicles, are the most common source of persistent wound infections and are disreputably resistant to antibiotic therapy.

Market Insights

Mode of mechanism, application, and geography are the three segments of the global anti-biofilm wound dressing industry. The chemical (iodine, ionic silver, and ethylenediaminetetraacetic acid (EDTA)), physical (pulse electrical field, manual debridement, and ultrasound debridement), and biological (lactoferrin, dispersin B, and bacteriophage) are all segmentations of the mode of mechanism segment. Among them, the chemical segment achieved the leading market share in 2021. In the early phases of microbial colonization, biofilm is created via a variety of potentially reversible processes. As a result, as biofilm formation continues and disruption and eradication grow more difficult, chemicals become increasingly critical. Based on application, the segmentation includes chronic wounds and acute wounds. In 2021, the acute wounds section accounted for the majority of the share.

Global Anti-Biofilm Wound Dressing Market Regional Analysis

North America, Latin America, Asia-Pacific, Europe, and the Middle East & Africa (ME&A) are the segmentation of the global anti-biofilm wound dressing industry. Among all the regions, North America conquered the maximum market share in 2021. The growing cases of chronic disorders in the region are likely to support the regional growth in the coming years. Chronic diseases, which are generally incurable and continuous, impact around 133 million Americans, or more than 40% of the country's entire population. That number is expected to rise to 157 million by 2020, with 81 million of them having multiple illnesses. About half of all people have a chronic condition, and about 8% of children aged 5 to 17 have limited activities due to at least one chronic disease or impairment, according to their parents. In addition, the existence of advanced healthcare facilities and leading players in the region will spur the demand for the anti-biofilm wound dressing industry.

Global Anti-Biofilm Wound Dressing Industry Segment Analysis

Mode of Mechanism Segments

·         Physical

o   Pulse Electrical Field

o   Manual Debridement

o   Ultrasound Debridement

·         Chemical

o   Iodine

o   Ionic Silver

o   EDTA

o   Others

·         Biological

o   Lactoferrin

o   Bacteriophage

o   Dispersin B

o   Others

Application Segments

·         Acute Wounds

·         Chronic Wounds

Anti-Biofilm Wound Dressing Market Top Companies

The major players in the market are identified in this section of the report. Coloplast A/S, 3M, ConvaTec Group plc, Smith & Nephew PLC, BioVersys AG, URGO, Mölnlycke Health Care AB, and Imbed Biosciences are the leading players profiled in the research report.

Anti-Biofilm Wound Dressing Market Regions

North America

·         U.S.

·         Canada

Europe

·         U.K.

·         Germany

·         France

·         Spain

·         Rest of Europe

Latin America

·         Brazil

·         Mexico

·         Rest of Latin America

Asia-Pacific

·         China

·         Japan

·         India

·         Australia

·         South Korea

·         Rest of Asia-Pacific

Middle East & Africa

·         GCC

·         South Africa

·         Rest of Middle East & Africa